Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).

Keiji Yoshinaga, Hiroshi Saeki, Eiji Oki, Masaru Morita, Tetsuo Ikeda, Keishi Sugimachi, Yo Ichi Yamashita, Toru Ikegami, Hideaki Uchiyama, Tomoharu Yoshizumi, Yuji Soejima, Hirofumi Kawanaka, Koshi Mimori, Masayuki Watanabe, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We previously reported that PSK-induced lymphocyte blastogenesis reaction (PSK-stimulation index; PSK-SI) may be a prognostic marker for immunochemotherapy using PSK in gastrointestinal cancer patients. In this study we evaluated the usefulness of PSK-SI as a prognostic marker for PSK therapy at higher and lower serum immunosuppressive acidic protein (IAP) levels. 98 gastric and 135 colorectal cancer patients were analyzed. PSK-SI and serum IAP levels were measured preoperatively. After operation, patients received UFT and PSK for two years. There were no differences between patients with higher and those with lower PSK-SI with respect to the clinicopathological factors. In patients with higher serum IAP levels (> or = 500 microg/ml), recurrence-free survival (RFS) and overall survival (OS) were apparently more favorable in the higher PSK-SI group (gastric cancer; > or = 1.75, colorectal cancer; > or = 2.1) than in lower PSK-SI group, although the differences were not significant. Serum IAP levels and PSK-SI may be useful markers for prediction of response to immunochemotherapy using PSK, although further studies are necessary.

Original languageEnglish
Pages (from-to)549-558
Number of pages10
JournalFukuoka igaku zasshi = Hukuoka acta medica
Volume104
Issue number12
Publication statusPublished - Jan 1 2013

Fingerprint

Tegafur
Uracil
Proteins
Serum
krestin
Colorectal Neoplasms
Gastrointestinal Neoplasms
Survival
Lymphocyte Activation
Stomach Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yoshinaga, K., Saeki, H., Oki, E., Morita, M., Ikeda, T., Sugimachi, K., ... Maehara, Y. (2013). Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). Fukuoka igaku zasshi = Hukuoka acta medica, 104(12), 549-558.

Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). / Yoshinaga, Keiji; Saeki, Hiroshi; Oki, Eiji; Morita, Masaru; Ikeda, Tetsuo; Sugimachi, Keishi; Yamashita, Yo Ichi; Ikegami, Toru; Uchiyama, Hideaki; Yoshizumi, Tomoharu; Soejima, Yuji; Kawanaka, Hirofumi; Mimori, Koshi; Watanabe, Masayuki; Maehara, Yoshihiko.

In: Fukuoka igaku zasshi = Hukuoka acta medica, Vol. 104, No. 12, 01.01.2013, p. 549-558.

Research output: Contribution to journalArticle

Yoshinaga, K, Saeki, H, Oki, E, Morita, M, Ikeda, T, Sugimachi, K, Yamashita, YI, Ikegami, T, Uchiyama, H, Yoshizumi, T, Soejima, Y, Kawanaka, H, Mimori, K, Watanabe, M & Maehara, Y 2013, 'Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).', Fukuoka igaku zasshi = Hukuoka acta medica, vol. 104, no. 12, pp. 549-558.
Yoshinaga, Keiji ; Saeki, Hiroshi ; Oki, Eiji ; Morita, Masaru ; Ikeda, Tetsuo ; Sugimachi, Keishi ; Yamashita, Yo Ichi ; Ikegami, Toru ; Uchiyama, Hideaki ; Yoshizumi, Tomoharu ; Soejima, Yuji ; Kawanaka, Hirofumi ; Mimori, Koshi ; Watanabe, Masayuki ; Maehara, Yoshihiko. / Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). In: Fukuoka igaku zasshi = Hukuoka acta medica. 2013 ; Vol. 104, No. 12. pp. 549-558.
@article{058f421cef6f46698d165883b59da956,
title = "Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).",
abstract = "We previously reported that PSK-induced lymphocyte blastogenesis reaction (PSK-stimulation index; PSK-SI) may be a prognostic marker for immunochemotherapy using PSK in gastrointestinal cancer patients. In this study we evaluated the usefulness of PSK-SI as a prognostic marker for PSK therapy at higher and lower serum immunosuppressive acidic protein (IAP) levels. 98 gastric and 135 colorectal cancer patients were analyzed. PSK-SI and serum IAP levels were measured preoperatively. After operation, patients received UFT and PSK for two years. There were no differences between patients with higher and those with lower PSK-SI with respect to the clinicopathological factors. In patients with higher serum IAP levels (> or = 500 microg/ml), recurrence-free survival (RFS) and overall survival (OS) were apparently more favorable in the higher PSK-SI group (gastric cancer; > or = 1.75, colorectal cancer; > or = 2.1) than in lower PSK-SI group, although the differences were not significant. Serum IAP levels and PSK-SI may be useful markers for prediction of response to immunochemotherapy using PSK, although further studies are necessary.",
author = "Keiji Yoshinaga and Hiroshi Saeki and Eiji Oki and Masaru Morita and Tetsuo Ikeda and Keishi Sugimachi and Yamashita, {Yo Ichi} and Toru Ikegami and Hideaki Uchiyama and Tomoharu Yoshizumi and Yuji Soejima and Hirofumi Kawanaka and Koshi Mimori and Masayuki Watanabe and Yoshihiko Maehara",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "104",
pages = "549--558",
journal = "Fukuoka Acta Medica",
issn = "0016-254X",
publisher = "福岡医学会",
number = "12",

}

TY - JOUR

T1 - Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).

AU - Yoshinaga, Keiji

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Morita, Masaru

AU - Ikeda, Tetsuo

AU - Sugimachi, Keishi

AU - Yamashita, Yo Ichi

AU - Ikegami, Toru

AU - Uchiyama, Hideaki

AU - Yoshizumi, Tomoharu

AU - Soejima, Yuji

AU - Kawanaka, Hirofumi

AU - Mimori, Koshi

AU - Watanabe, Masayuki

AU - Maehara, Yoshihiko

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We previously reported that PSK-induced lymphocyte blastogenesis reaction (PSK-stimulation index; PSK-SI) may be a prognostic marker for immunochemotherapy using PSK in gastrointestinal cancer patients. In this study we evaluated the usefulness of PSK-SI as a prognostic marker for PSK therapy at higher and lower serum immunosuppressive acidic protein (IAP) levels. 98 gastric and 135 colorectal cancer patients were analyzed. PSK-SI and serum IAP levels were measured preoperatively. After operation, patients received UFT and PSK for two years. There were no differences between patients with higher and those with lower PSK-SI with respect to the clinicopathological factors. In patients with higher serum IAP levels (> or = 500 microg/ml), recurrence-free survival (RFS) and overall survival (OS) were apparently more favorable in the higher PSK-SI group (gastric cancer; > or = 1.75, colorectal cancer; > or = 2.1) than in lower PSK-SI group, although the differences were not significant. Serum IAP levels and PSK-SI may be useful markers for prediction of response to immunochemotherapy using PSK, although further studies are necessary.

AB - We previously reported that PSK-induced lymphocyte blastogenesis reaction (PSK-stimulation index; PSK-SI) may be a prognostic marker for immunochemotherapy using PSK in gastrointestinal cancer patients. In this study we evaluated the usefulness of PSK-SI as a prognostic marker for PSK therapy at higher and lower serum immunosuppressive acidic protein (IAP) levels. 98 gastric and 135 colorectal cancer patients were analyzed. PSK-SI and serum IAP levels were measured preoperatively. After operation, patients received UFT and PSK for two years. There were no differences between patients with higher and those with lower PSK-SI with respect to the clinicopathological factors. In patients with higher serum IAP levels (> or = 500 microg/ml), recurrence-free survival (RFS) and overall survival (OS) were apparently more favorable in the higher PSK-SI group (gastric cancer; > or = 1.75, colorectal cancer; > or = 2.1) than in lower PSK-SI group, although the differences were not significant. Serum IAP levels and PSK-SI may be useful markers for prediction of response to immunochemotherapy using PSK, although further studies are necessary.

UR - http://www.scopus.com/inward/record.url?scp=84900014757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900014757&partnerID=8YFLogxK

M3 - Article

C2 - 24693683

AN - SCOPUS:84900014757

VL - 104

SP - 549

EP - 558

JO - Fukuoka Acta Medica

JF - Fukuoka Acta Medica

SN - 0016-254X

IS - 12

ER -